Hamamatsu Photonics K.k. · TSE:6965

Hamamatsu Photonics K.k — FY2022 Earnings Presentation

35 slides from Hamamatsu Photonics K.k's earnings presentation, November 2022

  1. Slide 1: Fiscal Year ended September 30, 2022 Financial Report

    Hamamatsu Photonics K.K. Fiscal Year ended September 30, 2022 Financial Report Tokyo Stock Exchange : 6965 November, 2022 🄫 Hamamatsu Photonics K.K. and its affiliates. All Rights Reserved. 1

  2. Slide 2: Notes

    Notes  This material is not intended to be a solicitation to buy or sell any securities of Hamamatsu Photonics K.K.  The information contained in this material is based on data available as of making it. No guarantees, promises are made as to its accuracy or completeness.  This material includes

  3. Slide 3: Summary of results; Medium-term plan

    1. Summary of results 2. Medium-term plan 🄫 Hamamatsu Photonics K.K. and its affiliates. All Rights Reserved. 3

  4. Slide 4: Summary of financial results FY2022 Highlights

    Summary of financial results FY2022 Highlights  Sales was 208.8 billion yen, Operating profit was 56.9 billion yen. We achieved the mid-term plan announced last year two years ahead of schedule. And we reached record high for the second consecutive year.  In all segments, sales increased and segme

  5. Slide 5: Financial results

    Financial results Unit :Million Yen Y/Y Sales FY2021 FY2022 Amount Ratio  Demand expanded in all industries Sales 169,026 208,803 39,777 23.5%  Weaker yen also impacted on our Gross profit 83,395 112,381 business (%) 28,986 34.8% • Impact by currency fluctuation +10 billion yen (49.3%) (53.8%) Ope

  6. Slide 6: Analysis fluctuation to operating profit 2021-2022

    Analysis fluctuation to operating profit 2021-2022 Unit :Million Yen 70,000 *Excluding currency exchange effects Increase of SG & Impact by Amount due A and R & D currency 60,000 Increase of to change in expenses fluctuation gross profit by gross margin sales increase + 8,249 50,000 + 4,267 (4,493)

  7. Slide 7: Sales by application

    Sales by application Unit :Million Yen Y/Y Medical-bio instrument Application FY2021 FY2022  Demand for radiographic testing, mainly for Amount Ratio high performance equipment of X-ray CT and PET expanded Medical-bio instrument 68,985 79,496 10,511 15.2%  Demand for laboratory testing, mainly for

  8. Slide 8: FY2022 sales by application

    FY2022 sales by application Consumer Others / not classified Information / Optical / photographic instrument communication instrument 3.6% instrument 1.1% 0.7% Radiographic testing 0.8% 25.1% Transport instrument 2.5% Measuring instrument 4.6% Academic research Others 5.0% 18.2% Medical-bio Analytic

  9. Slide 9: Financial results by business segment

    Financial results by business segment Unit :Million Yen Account Y/Y Electron tube Segment FY2021 FY2022 item  Strong demand for semiconductor Amount Ratio continued, and market for Li-ion battery testing expanded Sales 66,032 82,538 16,506 25.0% • Operating margin +5.6P Electron tube Operating 22,6

  10. Slide 10: Sales by region

    Sales by region FY2021 FY2022 North Europe America Europe North 22.9% 23.4% 21.4% America 26.1% Asia Japan Asia Japan 27.4% 26.2% 27.7% 24.7% Unit :Million Yen Europe Asia (of which China) Japan North America FY2021 38,716 46,320 (28,129) 44,243 39,487 FY2022 44,685 57,753 (37,479) 51,540 54,526 Amo

  11. Slide 11: Capital investment / Depreciation / R&D expense

    Capital investment / Depreciation / R&D expense Unit :Million Yen Capital investment / Depreciation R & D expense and ratio of R & D expense to sales 25,000 25,000 6.7% 7.0% 20,427 6.0% 20,000 20,000 5.4% 5.0% 15,000 12,354 15,000 12,982 12,402 11,367 11,269 4.0% 10,000 10,000 3.0% 5,000 5,000 2.0%

  12. Slide 12: Summary of results; Medium-term plan

    1. Summary of results 2. Medium-term plan 🄫 Hamamatsu Photonics K.K. and its affiliates. All Rights Reserved. 12

  13. Slide 13: FY2023 Outlook and Medium-term plan

    FY2023 Outlook and Medium-term plan FY2023 Outlook  Sales to be 236.2 billion yen (+27.3 billion yen or +13.1% Y/Y) Sales is expected to reach record high because of demand growth in many industries.  Net profit to be 42.4 billion yen (+1.1 billion yen or +2.7% Y/Y) Net profit is expected to reach

  14. Slide 14: Sales & profit through FY2025

    Sales & profit through FY2025 (Sales) Unit :Million Yen 280,000 260,000 CAGR 240,000 220,000 200,000 8.4％ 180,000 160,000 (FY2022 - FY2025) 140,000 120,000 High growth is expected in 100,000 non-destructive testing (for FY2023 FY2024 FY2025 Li-ion battery testing) and FY2020 FY2021 FY2022 transport

  15. Slide 15: Financial plan

    Financial plan Unit :Million Yen FY2023 Y/Y Sales FY2022 (Plan) Amount Ratio  Expanding demand in many Sales 208,803 236,200 27,397 13.1% industries continues Gross profit 112,381 128,400 (%) 16,019 14.3% *Impact by currency fluctuation:+3.0 billion yen (53.8%) (54.4%) Operating profit 56,983 58,50

  16. Slide 16: Operating profit fluctuation FY2022 to FY2023

    *Excluding currency exchange effects Unit :Million Yen 80,000 Increase of gross Amount due to Increase of SG & A profit by sales change in gross and R & D Impact by increase margin expenses currency 70,000 0 fluctuation +１2,992 (13,985 ) + 2,510 60,000 50,000 ＄:124.55→130.00 €:134.51→135.00 RMB:18.1

  17. Slide 17: Sales plan by application

    Sales plan by application Unit :Million Yen FY2023 Y/Y Medical-bio instrument Application FY2022 (Plan) Amount Ratio  Demand for radiographic testing, mainly for X- ray CT expands Medical-bio  Demand for laboratory testing, mainly for instrument 79,496 83,520 4,024 5.1% blood testing expands, whil

  18. Slide 18: Financial plan by business segment

    Financial plan by business segment Account FY2023 Y/Y Electron tube Segment FY2022 item (Plan) Amount Ratio  Market for Li-ion battery testing continues to grow (Reinforcing production system) Sales 82,538 87,600 5,062 6.1% • Operating margin (2.2P) Electron tube Operating 32,915 33,000 profit 85 0

  19. Slide 19: Capital investment / Depreciation / R&D expense

    Capital investment / Depreciation / R&D expense Unit : Million Yen Capital investment / Depreciation R & D expense and ratio of R & D expense to sales 50,000 30,000 8.0% 41,200 40,100 6.6％ 40,000 25,000 6.5％ 6.3％ 7.0% 5.4％ 6.0% 30,000 27,600 22,300 20,000 16,700 16,800 15,400 5.0% 20,427 20,300 15,0

  20. Slide 20: Group companies and locations

    Asia Americas HAMAMATSU PHOTONICS K.K. HAMAMATSU CORPORATION Headquarters Main Office / California Office HAMAMATSU PHOTONICS (CHINA)Co., Ltd. PHOTONICS MANAGEMENT Corp. Main Office / Shanghai Branch ENERGETIQ TECHNOLOGY, Inc. / Shenzhen Branch / Wuhan Branch BEIJING HAMAMATSU PHOTON TECHNIQUES INC.

  21. Slide 21: 🄫 Hamamatsu Photonics K.K. and its affiliates. All Rights Reserved.

    🄫 Hamamatsu Photonics K.K. and its affiliates. All Rights Reserved. 21

  22. Slide 22: Fiscal Year ended September 30, 2022 Data book

    Hamamatsu Photonics K.K. Fiscal Year ended September 30, 2022 Data book Tokyo Stock Exchange : 6965 November. 2022 🄫 Hamamatsu Photonics K.K. and its affiliates. All Rights Reserved. 22

  23. Slide 23: Notes

    Notes  This material is not intended to be a solicitation to buy or sell any securities of Hamamatsu Photonics K.K.  The information contained in this material is based on data available as of making it. No guarantees, promises are made as to its accuracy or completeness.  This material includes

  24. Slide 24: Financial results and plan

    Financial results and plan Unit :Million Yen FY2021 FY2022 FY2023 (Plan) FY2024 (Plan) FY2025 (Plan) 1st half 2nd half Year % 1st half 2nd half Year % 1st half 2nd half Year % Year % Year % Sales 79,342 89,684 169,026 100.0 100,516 108,286 208,803 100.0 115,300 120,900 236,200 100.0 252,300 100.0 26

  25. Slide 25: Sales by application

    Sales by application Unit :Million Yen FY2021 FY2022 FY2023 (Plan) Application st nd st nd st 1 half 2 half Year % 1 half 2 half Year % 1 half 2nd half Year % Radiographic testing 21,523 23,917 45,441 26.9 25,666 26,676 52,342 25.1 27,097 27,814 54,912 23.2 Medical-bio Laboratory testing 10,360 10,3

  26. Slide 26: Sales by application of Electron tube segment

    Sales by application of Electron tube segment Unit :Million Yen FY2021 FY2022 FY2023 (Plan) Application st nd st nd st 1 half 2 half Year % 1 half 2 half Year % 1 half 2nd half Year % Radiographic testing 4,794 5,355 10,150 15.4 6,055 6,200 12,255 14.8 5,863 5,422 11,286 12.9 Medical-bio Laboratory

  27. Slide 27: Sales by application of Opto-semiconductor segment

    Sales by application of Opto-semiconductor segment Unit :Million Yen FY2021 FY2022 FY2023 (Plan) Application st nd st nd st 1 half 2 half Year % 1 half 2 half Year % 1 half 2nd half Year % Radiographic testing 16,726 18,557 35,284 45.0 19,610 20,476 40,086 41.4 21,233 22,392 43,625 40.8 Medical-bio

  28. Slide 28: Sales by application of Imaging and measurement instruments segment

    Sales by application of Imaging and measurement instruments segment Unit :Million Yen FY2021 FY2022 FY2023 (Plan) Application st nd st nd st 1 half 2 half Year % 1 half 2 half Year % 1 half 2nd half Year % Radiographic testing 0 2 2 0.0 0 0 0 0.0 0 0 0 0.0 Medical-bio Laboratory testing 2,617 2,589

  29. Slide 29: Major subsidiaries income statements

    Major subsidiaries income statements Local currency (thousand local currency) Yen (million yen) Company Account item FY2021 FY2022 FY2021 FY2022 Year % Year % Year Year Sales 442,175 100.0 525,886 100.0 47,551 65,500 Hamamatsu Corporation Gross profit 80,273 18.2 102,742 19.5 8,632 12,796 sales comp

  30. Slide 30: 2021-2025 plan by business segment

    2021-2025 plan by business segment Unit :Million Yen FY2021 FY2022 FY2023 (Plan) FY2024 FY2025 (Plan) (Plan) 1st half 2nd half Year 1st half 2nd half Year 1st half 2nd half Year Electron tube 30,448 35,584 66,032 40,062 42,476 82,538 44,250 43,350 87,600 91,350 96,450 Opto- 36,764 41,654 78,418 46,9

  31. Slide 31: 2021-2025 plan of Electron tube

    2021-2025 plan of Electron tube Unit :Million Yen FY2023 FY2024 FY2025 FY2021 FY2022 (Plan) (Plan) (Plan) 1st half 2nd half Year % 1st half 2nd half Year % 1st half 2nd half Year % Year % Year % Sales 30,448 35,584 66,032 100.0 40,062 42,476 82,538 100.0 44,250 43,350 87,600 100.0 91,350 100.0 96,45

  32. Slide 32: 2021-2025 plan of Opto-semiconductor

    2021-2025 plan of Opto-semiconductor Unit :Million Yen FY2023 FY2024 FY2025 FY2021 FY2022 (Plan) (Plan) (Plan) 1st half 2nd half Year % 1st half 2nd half Year % 1st half 2nd half Year % Year % Year % Sales 36,764 41,654 78,418 100.0 46,955 49,856 96,812 100.0 52,750 54,150 106,900 100.0 106,350 100.

  33. Slide 33: 2021-2025 plan of Imaging & measurement instrument

    2021-2025 plan of Imaging & measurement instrument Unit :Million Yen FY2023 FY2024 FY2025 FY2021 FY2022 (Plan) (Plan) (Plan) 1st half 2nd half Year % 1st half 2nd half Year % 1st half 2nd half Year % Year % Year % Sales 10,432 11,111 21,543 100.0 11,993 14,688 26,681 100.0 16,400 15,850 32,250 100.0

  34. Slide 34: Capital investment, R & D expenses and depreciation

    Capital investment, R & D expenses and depreciation Unit :Million Yen FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 Ratio to Ratio to Ratio to Ratio to Ratio to Ratio to Amount Amount Amount Amount Amount Amount sales (%) sales (%) sales (%) sales (%) sales (%) sales (%) 1st quarter 4,441 14.8 4,235 12.

  35. Slide 35: 🄫 Hamamatsu Photonics K.K. and its affiliates. All Rights Reserved.

    🄫 Hamamatsu Photonics K.K. and its affiliates. All Rights Reserved. 35

Hamamatsu Photonics K.K. — FY2022 Earnings Presentation on 6ix